Meeting program
Thursday, April 18
*All times are in EET.
16:00 - 19:00 EET Satellite symposia
- Novartis
- Hoffman-La Roche
- Takeda
Various satellite symposia will take place the day before the meeting for national and regional participants.
Friday, April 19
*All times are in EET.
08:45 - 09:00 EET Opening remarks
- A Ivanaj (Albania), A Cili (Albania), D Coriu (Romania), K Döhner (Germany) & M Guenova (Bulgaria)
09:00 - 10:30 EET Session 1: Acute myeloid leukemia - The role of BMT
Chair: I Micheva (Bulgaria)
- State-of-the-Art lecture: Why BMT for AML in 2024?
J Esteve (Spain) - Juvenile myelomonocytic leukemia (JMML) with familial neurofibromatosis type 1 (NF1) and Stem Cell transplantation
- G Rodica (Moldova)
- Allogeneic hematopoietic stem cell transplant in AML patients in North Macedonia - Single center experience
L Chadievski (North Macedonia) - The role of salvage therapy before allo-HSCT in R/R AML
E Tekgündüz (Türkiye) - Allogeneic stem cell transplant in TP53-mutated acute myeloid leukemia
M Stamouli (Greece) - Panel discussion
All speakers
10:30 - 10:45 EET Coffee break
10:45 - 12:15 EET Session 2: The role of ASCT in the management of patients with multiple myeloma in 2024
Chairs: E Grouzi (Greece) & D Coriu (Romania)
- State-of-the-Art lecture: The role of BMT in treatment of multiple myeloma in 2024
D Coriu (Romania) - Is there rationale for the salvage ASCT in the era of new treatment modalities for multiple myeloma
J Bila (Serbia) - BMT vs CAR-T cell therapy in R/R multiple myeloma patients
A Cili (Albania) - Therapy with bispecific antibodies in patients with multiple myeloma: Romanian experience
S Badelita (Romania) - Autologous transplantation for multiple myeloma in the era of new drugs
I Mandac-Smoljanović (Croatia) - Virtual - Panel discussion
All speakers
12:15 - 13:15 EET Lunch
13:15 - 14:45 EET Session 3: Acute lymphoblastic leukemia - Therapy & BMT
Chairs: S Unal Cangül (Türkiye) & S Buruiana (Moldova)
- State-of-the-Art lecture: BMT in treatment of ALL in the era of immunotherapy and targeted therapy
JM Ribera (Spain) - Early results of Carfilzomib/Melphalan (KMel) conditioning regimen in newly diagnosed patients with multiple myeloma fit for autologous stem cell transplantation
Y Petriv (Bulgaria) - Significance of MRD on HSCT outcome in pediatric ALL patients
O Tüfekçi (Türkiye) - Hematopoietic stem cell transplantation for acute leukemia - Single center activity from Bulgaria
G Michaylov (Bulgaria) - Panel discussion
All speakers
14:45 - 15:00 EET Coffee break
15:00 - 16:30 EET Session 4: Non-Hodgkin Lymphoma: Therapy for relapsed / refractory setting - Focused on new therapy and BMT
Chairs: E Kryeziu (Kosovo) & C Catan (Moldova)
- State-of-the-Art lecture: The role of cellular therapy in the treatment of B cell lymphoma
M Gomes da Silva (Portugal) - Hepatosplenic T-cell lymphoma a rare and aggressive disease
A Ukimeraj (Kosovo) - Advances in the treatment of R/R mantle cell lymphomas
E Birtaş (Türkiye) - New therapy in lymphoma
OD Preda (Romania) - The relationship between experience and outcome in recently opened autologous transplant center in Split
A Miljak (Croatia) - Panel discussion
All speakers
16:30 - 18:00 EET Session 5: Hodgkin lymphoma: Therapy for relapsed / refractory setting - Focused on new therapy and BMT
Chairs: M Cem Ar (Türkiye) & S Krasniqi (Kosovo)
- State-of-the-Art lecture: The role of BMT in treatment of Hodgkin Lymphoma
I Aurer (Croatia) - Latest developments in new therapies for R/R Hodgkin lymphoma
U Yılmaz (Türkiye) - Checkpoint inhibitors in relapsed/refractory classical Hodgkin lymphoma: Update on current and upcoming applications
T Vassilakopoulos (Greece) - Current data on treatment of relapsed and refractory HL in North Macedonia
A Pivkova Veljanovska (North Macedonia) - Hodgkin lymphoma: Treatment and challenges
F Gashi (Kosovo) - Panel discussion
All speakers
18:00 - 18:30 Closing remarks
- A Ivanaj (Albania), A Cili (Albania), D Coriu (Romania), K Döhner (Germany) & M Guenova (Bulgaria)
Back